Home / Peptide Center / CJC-1295 Not FDA-Approved CJC-1295: evidence, status & safety CJC-1295 is a long-acting growth hormone-releasing hormone analog studied for its effects
Peptide Center / CJC-1295 Not FDA-approved CJC-1295: evidence, status & safety CJC-1295 is a long-acting growth-hormone-releasing hormone analog studied for its effects on GH and
BPC-157 is a synthetic peptide promoted online for tendon, ligament, muscle, gastrointestinal and postoperative healing. It is not an FDA-approved human drug.
Retatrutide is an investigational triple receptor agonist targeting GIP, GLP-1 and glucagon receptors. Multiple Phase 3 studies have reported positive topline results, but FDA has not approved it for any condition.
Tirzepatide is a peptide-based dual GIP and GLP-1 receptor agonist. FDA-approved products have product-specific indications including type 2 diabetes, chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity.
Semaglutide is a GLP-1 receptor agonist peptide medicine. FDA-approved products now include injection and tablet formulations with product-specific indications spanning type 2 diabetes, cardiovascular risk reduction, chronic weight management and eligible adults with MASH.
A practical checklist for patients trying to distinguish a legitimate prescription and regulated pharmacy from a counterfeit, misbranded, contaminated or research-only product.
